Competitive antagonism of the mouse 5-hydroxytryptamine3 receptor by bisindolylmaleimide I, a 'selective' protein kinase C inhibitor

Steven J. Coultrap, Hongwei Sun, Thomas E. Tenner, Tina K. Machu

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


We examined the effects of several protein kinase C (PKC) inhibitors on the murine 5-hydroxytryptamine3 (5-HT3) receptor to determine whether they acted directly on the receptor. The 5-HT-evoked currents in Xenopus laevis oocytes expressing the recombinant 5-HT3 receptor were measured with the two-electrode voltage-clamp technique. The PKC inhibitors bisindolylmaleimide I (BIM, GF109203x) and staurosporine, but not calphostin C or chelerythrine, decreased the 5-HT3 receptor-mediated currents when coapplied with 5-HT. BIM blocked 0.5 μM 5-HT-elicited currents with an IC50 value of 7 nM, whereas in the presence of 5 μM staurosporine, 42% inhibition of 0.5 μM 5-HT- mediated currents was observed. Increasing concentrations of BIM resulted in a rightward shift of the 5-HT concentration-response curve, without altering efficacy. A Schild plot was generated, which had a slope of -1.01, suggesting competitive antagonism. The K(i) value of BIM was determined to be 29 nM. To confirm competitive antagonism, a competitive binding assay was performed on Sf21 insect cells infected with the mouse 5-HT3 receptor cDNA in a baculovirus expression vector. BIM completely displaced binding of the selective 5-HT3 receptor antagonist [3H]GR65630. BIM bound to the 5-HT3 receptor with a K(i) value of 61 nM, which was slightly less potent than that of the selective 5-HT3 receptor antagonist MDL72222 (27 nM). The PKC inhibitor BIM is a potent competitive antagonist at the 5-HT3 receptor.

Original languageEnglish
Pages (from-to)76-82
Number of pages7
JournalJournal of Pharmacology and Experimental Therapeutics
Issue number1
StatePublished - 1 Jul 1999


Dive into the research topics of 'Competitive antagonism of the mouse 5-hydroxytryptamine3 receptor by bisindolylmaleimide I, a 'selective' protein kinase C inhibitor'. Together they form a unique fingerprint.

Cite this